Peter Enderlin

Sara Nik

Will Hidell

Brian Kemp Dolliver

Joe Pantginis

Stephen Brozak

- Lisata Therapeutics, Inc. **(LSTA)** entered into a **worldwide Non-Exclusive License Agreement** with Catalent, Inc. on **October 8, 2025**.  **[320017_0000320017-25-000063_clbs-20251008.htm:1]** 
- Under the agreement, Lisata granted Catalent non-exclusive rights to utilize its novel iRGD cyclic peptide, **certepetide**, as an antibody drug conjugate (ADC) payload within Catalent's SMARTag® ADC platform.  **[320017_0000320017-25-000063_clbs-20251008.htm:1]** 
- Lisata is eligible to receive **up to $10.5 million** in aggregate pre-determined development milestone payments, in addition to tiered revenue sharing on future sales and/or partnerships.  **[320017_0000320017-25-000063_clbs-20251008.htm:1]** 
- Catalent will assume full responsibility for all research, development, and commercialization costs associated with the licensed intellectual property.  **[320017_0000320017-25-000063_clbs-20251008.htm:1]**

LISATA THERAPEUTICS (LSTA)